Euglycemic diabetic ketoacidosis in a patient with type 1 diabetes and SARS-CoV-2 pneumonia: case-report and review of the literature

Acta Clin Belg. 2022 Feb;77(1):113-117. doi: 10.1080/17843286.2020.1780390. Epub 2020 Jun 16.

Abstract

Objective: Recent publications on Coronavirus Disease-2019 (COVID-19) report that diabetic people with or without co-morbidities are at higher risk of developing severe and/or fatal illnesses.

Method and result: We report the first case of a 60-year-old man with a 27-year history of type 1 diabetes mellitus, infected by SARS-CoV-2 presenting with an euglycaemic ketoacidosis and an acute respiratory distress syndrome.

Conclusion: This case report reminds us of the importance of adjusting more recent glucose-lowering drugs, including sodium-glucose cotransporter 2 inhibitors, in the overall management of type 1 diabetic individuals during the ongoing COVID-19 outbreak.

Abbreviations: COVID-19: Coronavirus disease 2019 (SARS-CoV-2) virus, T1DM: Type 1 diabetes mellitus, T2DM: Type 2 diabetes mellitus, SGLT2i: Sodium-glucose cotransporter 2 inhibitor, DKA: diabetic ketoacidosis, euDKA: euglycaemic diabetic ketoacidosis.

Keywords: COVID-19; SARS-CoV-2; SGLT2i; euDKA; euglycaemic diabetic ketoacidosis; type 1 diabetes mellitus.

Publication types

  • Case Reports
  • Review

MeSH terms

  • COVID-19*
  • Diabetes Mellitus, Type 1* / complications
  • Diabetes Mellitus, Type 2* / complications
  • Diabetic Ketoacidosis* / etiology
  • Humans
  • Male
  • Middle Aged
  • SARS-CoV-2
  • Sodium-Glucose Transporter 2 Inhibitors*

Substances

  • Sodium-Glucose Transporter 2 Inhibitors